Literature DB >> 25705282

Ibrutinib, a novel agent in relapsed or refractory chronic lymphocytic leukemia.

Ana-Maria Ivanescu1, Madalina Oprea1, Andrei Turbatu1, Andrei Colita1, Anca Roxana Lupu1.   

Abstract

Entities:  

Year:  2014        PMID： 25705282      PMCID： PMC4296769     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN： 1841-9038


× No keyword cloud information.
  3 in total

1.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors:  Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

2.  BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Authors:  S Cheng; J Ma; A Guo; P Lu; J P Leonard; M Coleman; M Liu; J J Buggy; R R Furman; Y L Wang
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

Review 3.  Novel agents for chronic lymphocytic leukemia.

Authors:  Mei Wu; Akintunde Akinleye; Xiongpeng Zhu
Journal:  J Hematol Oncol       Date:  2013-05-16       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.